If you are in drug development it is important to maintain secrecy but at the same time the board needs to recognise the currency that is funding their research is the price of the shares. ATH434 is at least a two year time frame and during that time the cash burn will accelerate.
The shorter term kicker is PBT2 (ATH2?) which, if shown to be highly prospective, would add immediately to the stock price. There are two time frames to work and I wonder if they can walk and chew gum at the same time.
At least there could be disclosure of how many, and on what molecule, research projects are being funded by Alterity at tthe moment.
It would give me some comfort.
Ann: ATH Annual General Meeting Presentation, page-24
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.001(11.1%) |
Mkt cap ! $26.22M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $4.263K | 916.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 58 | 69165915 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 38212524 | 21 |
View Market Depth
| Last trade - 15.11pm 05/07/2024 (20 minute delay) ? |
| ATH (ASX) Chart |